MEDP Medpace Holdings, Inc.
Services-Commercial Physical & Biological Research · Nasdaq · SEC CIK 1668397 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY20.4%
TTM net income YoY19.6%
TTM EPS YoY25.9%
Revenue 3-yr CAGR16.8%
Net income 3-yr CAGR23.8%
Margins
Gross margin—
Operating margin21.4%
Net margin18.2%
FCF margin23.5%
EBITDA margin22.3%
Returns
ROE117.9%
ROA25.5%
ROIC (approx.)—
Asset turnover1.40x
Leverage & solvency
Liabilities / assets74.6%
Debt / equity0.00x
Current ratio0.83x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.40x
Accruals ratio-10.1%
Payout ratio—
Capex / revenue2.0%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $2.53B | $2.11B | $1.89B | $1.46B | $1.14B |
| SG&A expense | $197.56M | $180.18M | $161.35M | $131.40M | $108.42M |
| Operating income | $534.93M | $446.87M | $336.82M | $278.70M | $198.62M |
| Pretax income | $542.38M | $475.92M | $335.68M | $282.86M | $201.85M |
| Income tax | $91.25M | $71.54M | $52.87M | $37.49M | $20.00M |
| Net income | $451.12M | $404.39M | $282.81M | $245.37M | $181.85M |
| EBITDA | $562.11M | $474.68M | $360.95M | $297.69M | $214.62M |
| EPS (basic) | 15.64 | 13.06 | 9.20 | 7.57 | 5.06 |
| EPS (diluted) | 15.28 | 12.63 | 8.88 | 7.28 | 4.81 |
| Weighted avg. shares (diluted) | 29.53M | 32.01M | 31.84M | 33.67M | 37.70M |
| Balance sheet | |||||
| Cash & equivalents | $497.05M | $669.44M | $245.45M | $28.27M | $461.30M |
| Receivables | $402.08M | $296.44M | $298.40M | $253.40M | $186.43M |
| Current assets | $989.62M | $1.03B | $593.83M | $333.96M | $690.91M |
| PP&E, net | $131.06M | $123.61M | $120.59M | $109.85M | $93.15M |
| Goodwill | $662.40M | $662.40M | $662.40M | $662.40M | $662.40M |
| Intangibles | $33.42M | $34.37M | $35.81M | $38.01M | $41.36M |
| Total assets | $1.98B | $2.10B | $1.66B | $1.35B | $1.66B |
| Current liabilities | $1.34B | $1.10B | $925.13M | $803.47M | $557.22M |
| Short-term debt | — | — | $0 | $50.00M | $0 |
| Total liabilities | $1.52B | $1.28B | $1.10B | $966.11M | $707.01M |
| Shareholders' equity | $459.07M | $825.54M | $558.95M | $386.39M | $952.93M |
| Shares outstanding | 28.37M | 30.63M | 30.75M | 31.09M | 36.01M |
| Cash flow statement | |||||
| Operating cash flow | $713.22M | $608.82M | $433.37M | $388.05M | $263.33M |
| Capital expenditure | $31.36M | $36.55M | $36.65M | $36.88M | $28.27M |
| Free cash flow | $681.87M | $572.27M | $396.73M | $351.17M | $235.06M |
| Investing cash flow | -$31.14M | -$28.31M | -$34.63M | -$38.74M | -$31.36M |
| Financing cash flow | -$860.39M | -$154.01M | -$182.64M | -$775.77M | -$44.45M |
| Depreciation & amortization | $27.18M | $27.81M | $24.13M | $18.99M | $16.00M |
| Stock-based compensation | $34.79M | $25.51M | $20.52M | $21.41M | $14.47M |
| Share buybacks | $917.39M | $169.87M | $144.02M | $847.85M | $62.10M |
Free plan shows the latest 5 periods; Pro shows all 11 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.